.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Queensland Health
Fuji
Dow
Farmers Insurance
US Army
AstraZeneca
Deloitte
Citi

Generated: November 19, 2017

DrugPatentWatch Database Preview

Dantrolene sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for dantrolene sodium and what is the scope of dantrolene sodium patent protection?

Dantrolene sodium
is the generic ingredient in four branded drugs marketed by Mylan Institutional, Par Sterile Products, Impax Labs, Hikma Pharms, Us Worldmeds, Eagle Pharms, and Elite Labs Inc, and is included in eight NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dantrolene sodium has eight patent family members in five countries.

There are five drug master file entries for dantrolene sodium. Ten suppliers are listed for this compound.

Pharmacology for dantrolene sodium

Medical Subject Heading (MeSH) Categories for dantrolene sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms
RYANODEX
dantrolene sodium
FOR SUSPENSION;INTRAVENOUS205579-001Jul 22, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Elite Labs Inc
DANTROLENE SODIUM
dantrolene sodium
CAPSULE;ORAL076686-003Oct 24, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Elite Labs Inc
DANTROLENE SODIUM
dantrolene sodium
CAPSULE;ORAL076686-001Oct 24, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Impax Labs
DANTROLENE SODIUM
dantrolene sodium
CAPSULE;ORAL076856-002Mar 1, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Us Worldmeds
REVONTO
dantrolene sodium
INJECTABLE;INJECTION078378-001Jul 24, 2007APRXNoNo► Subscribe► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
INJECTABLE;INJECTION018264-001Approved Prior to Jan 1, 1982APRXYesYes► Subscribe► Subscribe► Subscribe
Impax Labs
DANTROLENE SODIUM
dantrolene sodium
CAPSULE;ORAL076856-003Mar 1, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Hikma Pharms
DANTROLENE SODIUM
dantrolene sodium
INJECTABLE;INJECTION204762-001Jun 19, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dantrolene sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
INJECTABLE;INJECTION018264-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Par Sterile Products
DANTRIUM
dantrolene sodium
CAPSULE;ORAL017443-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: dantrolene sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,789,090Treatment using dantrolene► Subscribe
9,271,964Treatment using dantrolene► Subscribe
9,603,840Treatment using dantrolene► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dantrolene sodium

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2005013919► Subscribe
Japan4880449► Subscribe
Japan2007525439► Subscribe
European Patent Office1603513► Subscribe
Canada2516667► Subscribe
World Intellectual Property Organization (WIPO)03000057► Subscribe
Australia2004262507► Subscribe
European Patent Office1435781► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Chubb
AstraZeneca
Medtronic
Merck
Cerilliant
Accenture
US Army
Teva
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot